By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Alza
Corp. et al. v. Par Pharmaceutical Inc. et al.
1:13-cv-01104;
filed June 19, 2013 in the District Court of Delaware
• Plaintiffs:
Alza Corp.; Janssen Pharmaceuticals Inc.
• Defendants:
Par Pharmaceutical Inc.; Actavis Elizabeth LLC; Actavis Inc.
Infringement of U.S. Patent No. 8,163,798 ("Methods and Devices for Providing Prolonged Drug Therapy," issued April 24, 2012) following a Paragraph IV certification as part of Par's filing of an ANDA to manufacture a generic version of Alza's Concerta® (methylphenidate hydrochloride, used to treat attention deficit hyperactivity disorder). View the complaint here.
Kissei
Pharmaceutical Co. Ltd. et al. v. Hetero USA Inc., et al.
1:13-cv-01091;
filed June 17, 2013 in the District Court of Delaware
• Plaintiffs:
Kissei Pharmaceutical Co. Ltd.; Watson Laboratories Inc.; Actavis Inc.
• Defendant: Sandoz
Inc.
Kissei
Pharmaceutical Co. Ltd. et al. v. Sandoz Inc.
1:13-cv-01092;
filed June 17, 2013 in the District Court of Delaware
• Plaintiffs:
Kissei Pharmaceutical Co. Ltd.; Watson Laboratories Inc.; Actavis Inc.
• Defendants:
Hetero USA Inc.; Hetero Labs Limited; Hetero Labs Ltd., Unit III
The complaints in these cases are substantially identical. Infringement of U.S. Patent No. 5,387,603 ("1,5,7-Trisubstituted Indoline Compounds and Salts Thereof," issued February 7, 1995) following a Paragraph IV certification as part of Hetero's filing of an ANDA to manufacture a generic version of Watson's Rapaflo® (silodosin, used to treat benign prostatic hyperplasia). View the Hetero complaint here.
AbbVie Inc.
v. Mylan Pharmaceuticals Inc.
1:13-cv-01072;
filed June 14, 2013 in the District Court of Delaware
Infringement of U.S. Patent Nos. 6,232,333 ("Pharmaceutical Composition," issued May 15, 2001), 7,141,593 ("Pharmaceutical Formulations," issued November 28, 2006), and 7,432,294 (same title, issued October 7, 2008) following a Paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of AbbVie's Norvir® (ritonavir, used to treat human immunodeficiency virus (HIV) infection). View the complaint here.
Insite Vision
Inc. et al. v. Mylan Pharmaceuticals Inc. et al.
3:13-cv-03720;
filed June 14, 2013 in the District Court of New Jersey
• Plaintiffs:
Insite Vision Inc.; Merck Sharp & Dohme Corp.; Inspire
Pharmaceuticals, Inc.; Pfizer Inc.
• Defendants:
Mylan Pharmaceuticals Inc.; Mylan Inc.
Infringement of U.S. Patent Nos. 6,861,411 ("Method of Treating Eye Infections with Azithromycin," issued March 1, 2001), 6,239,113 ("Topical Treatment or Prevention of Ocular Infections," issued May 29, 2001), 6,569,443 (same title, issued May 27, 2003), and 7,056,893 (same title, issued June 6, 2006), licensed to Inspire (now Merck), following a Paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of Merck's AzaSite® (azithromycin, used to treat bacterial conjunctivitis). View the complaint here.
Senju
Pharmaceutical Co., Ltd v. Apotex Inc. et al.
1:13-cv-04132;
filed June 14, 2013 in the Southern District of New York
• Plaintiff:
Senju Pharmaceutical Co., Ltd.
• Defendants:
Apotex Inc.; Apotex Corp.; Ista Pharmaceuticals, Inc; Bausch & Lomb
Inc.
Infringement of U.S. Patent No. 6,335,335 ("Prolonged-Action Eye Drop," issued January 1, 2002) following a Paragraph IV certification as part of Apotex's filing of an ANDA to manufacture a generic version of Senju's Istalol® (timolol maleate ophthalmic solution, 0.5%, used treat elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma). View the complaint here.
Comments